

Deferred registration: Phase I Trial: MAC code 'MAC215'

Submission date 17/06/2026	Recruitment status Recruiting	☐ Prospectively registered ☐ Protocol
Registration date 17/06/2026	Overall study status Deferred	☐ Statistical analysis plan ☐ Results
Last Edited 17/06/2026	Condition category Other	☐ Individual participant data ☒ Record updated in last year

Plain English summary of protocol

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.

Contact information

Type(s)

Public

Contact name

Mr Adam Uchimoto

Contact details

6027 Edgewood Bend Court
San Diego
United States of America
92130

-

auchimoto@neurocrine.com

Type(s)

Scientific

Contact name

Dr Per Dalen

Contact details

6027 Edgewood Bend Court
San Diego
United States of America

92130

-

pdalen@neurocrine.com

Type(s)

Principal investigator

Contact name

Dr Giuseppe Fiore

Contact details

Neuroscience Centre of Excellence, Citylabs, Nelson Street

Manchester

United Kingdom

M13 9NQ

+44 161 275 9966

giuseppefiore@macplc.com

Additional identifiers

Integrated Research Application System (IRAS)

1013343

Study information

Scientific Title

Deferred registration: Phase I Trial: MAC code 'MAC215' [Full scientific title to be added on or before the deferral expiry date]

Study objectives

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 10/04/2026, Wales REC 1 (Health and Care Research Wales, Castlebridge 4, 15-19 Cowbridge Road East, Cardiff, CF11 9AB, United Kingdom; -; Wales.REC1@wales.nhs.uk), ref: 26 /WA/0028

Primary study design

Interventional

Allocation

Randomized controlled trial

Masking

Blinded (masking used)

Control

Placebo

Assignment

Parallel

Purpose

Treatment

Study type(s)**Health condition(s) or problem(s) studied**

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.

Interventions

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Primary outcome(s)

1. [Outcome] measured using [measure] at [timepoint]. The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.

Key secondary outcome(s)**Completion date**

11/03/2027

Eligibility**Key inclusion criteria**

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

50 Years

Upper age limit

85 Years

Sex

All

Total final enrolment

0

Key exclusion criteria

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.

Date of first enrolment

22/05/2026

Date of final enrolment

15/02/2027

Locations

Countries of recruitment

United Kingdom

England

Scotland

Study participating centre

MAC Clinical Research Manchester

Citylabs 1.0

Nelson St

Manchester

England

M13 9NQ

Study participating centre

MAC Clinical Research Teesside

Clinical Research Centre

Sabatier Close

Stockton-on-Tees
England
TS17 6EW

Study participating centre
MAC Clinical Research Cannock
Clinical Research Centre
Exchange House
Watling Street
Cannock
South Staffordshire
England
WS11 0BN

Study participating centre
MAC Clinical Research Blackpool
Clinical Research Centre
Kaman Court
1 Faraday Way
Blackpool
England
FY2 0JH

Study participating centre
MAC Clinical Research Barnsley
Phoenix House
Maple Road
Barnsley
England
S75 3DL

Study participating centre
MAC Clinical Research Leeds
Monarch House
Wakefield Rd
Leeds
England
LS10 1DU

Study participating centre

MAC Clinical Research Liverpool

11 Tiger Court
King's Business Park
Liverpool
England
L34 1BH

Study participating centre**MAC Clinical Research Glasgow**

Clinical Research Centre, Ground Floor, Fleming Pavilion Todd Campus, West of Scotland Science
Park
Glasgow
England
G20 0XA

Sponsor information

Organisation

Neurocrine Biosciences (United States)

ROR

<https://ror.org/05d84mm26>

Funder(s)

Funder type**Funder Name**

Neurocrine Biosciences

Alternative Name(s)

Neurocrine Biosciences, Inc.

Funding Body Type

Government organisation

Funding Body Subtype

For-profit companies (industry)

Location

United States of America

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not expected to be made available